Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the use of Tislelizumab, an anti-PD-1 monoclonal antibody, in adults with previously treated locally advanced unresectable or metastatic solid tumors that have microsatellite instability-high MSI-H or mismatch repair deficient dMMR characteristics. This Phase 2, single-arm, multi-center, open-label study aims to assess the efficacy and safety of this immunotherapy in this specific cancer population. Participants will receive Tislelizumab as monotherapy. The study does not include a comparison group or placebo. Treatment details such as dosing schedules are not provided in the summary, but participants will be monitored for treatment response and safety over a period of up to two years. Throughout the study, participants will have measurable disease lesions assessed by independent and investigator review according to standardized criteria. Researchers will evaluate outcomes including objective response rate, duration and time to response, progression-free survival, disease control rate, overall survival, and safety based on adverse event reporting. The study duration includes up to two years of follow-up for these measurements.